Skip to content
OpenCapital
Get started

ImmunityBio, Inc. IBRX Share-Based Payment Award Options Outstanding - Number

Share-Based Payment Award Options Outstanding - Number at other companies

Incyte logo
IncyteINCY
——
Exelixis logo
ExelixisEXEL
——
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
——

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%—
Debt / equity0.1×—
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s share-based payment award options outstanding - number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ImmunityBio, Inc.'s share-based payment award options outstanding - number?
ImmunityBio, Inc. (IBRX) reported share-based payment award options outstanding - number of 23.4M in Q1 2026.
How has ImmunityBio, Inc.'s share-based payment award options outstanding - number changed year-over-year?
ImmunityBio, Inc.'s share-based payment award options outstanding - number decreased by 8.2% year-over-year, from 25.5M to 23.4M.
What is the long-term trend for ImmunityBio, Inc.'s share-based payment award options outstanding - number?
Over 5 years (2020 to 2025), ImmunityBio, Inc.'s share-based payment award options outstanding - number has grown at a 36.8% compound annual growth rate (CAGR), from 5M to 23.9M.